Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy

Mathew Zachariah, Mohamed Elshinawy*, Abdulhakim Alrawas, Wafa Bashir, Ismail Elbeshlawi, Surekha Tony, Yasser Wali

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The role of erythropoiesis-stimulating agents (ESAs) in the management of chemotherapy-induced anemia (CIA) is becoming increasingly recognized in the field of medical oncology, with paucity of data in pediatrics. We evaluated the efficacy and tolerability of a single-dose darbepoetin alfa, a long-acting ESA, given to 35 pediatric acute lymphoblastic leukemia (ALL) children during induction chemotherapy. Compared to a retrospective control group, the studied patients have required significantly less units of packed red blood cells (0.88 units/patient in the studied group versus 2.04 units in controls), with no major side effects. We recommend further prospective double-blinded studies with more tailored dosing regimens in pediatric ALL cases and solid tumors.

Original languageEnglish
Pages (from-to)442-447
Number of pages6
JournalPediatric Hematology and Oncology
Volume31
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • Anemia
  • Chemotherapy
  • Darbepoetin alfa
  • Leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy'. Together they form a unique fingerprint.

Cite this